Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
about
Are we there yet? The smallpox research agenda using variola virusSafety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study populationA Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccineRepeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbitsDevelopments in Viral Vector-Based Vaccines.Anti-Infectious Human Vaccination in Historical Perspective.How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?
P2860
Q21131362-B59A4FE1-6441-471B-9507-BC9AB6907F9BQ30151079-AB54A992-1EED-4581-8613-F967527F6643Q35447516-6F652D6A-BBAF-4903-AE5F-0063047AAE3EQ36057928-92B5DDBB-776F-47FE-947A-2F663FBE2F28Q36090390-B02A2160-50B5-4C09-AE22-1FC214B9AE59Q37135398-733ED000-0C46-42E8-BE12-5CE22A8E5587Q38582090-341A7E10-539C-4557-96E7-274DA07496D4Q40129444-8A6EC6F6-6A7B-42FE-8FD4-4BE16A6D929DQ41928044-00AA1091-E467-4C63-AC08-8DE2D2346048
P2860
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and immunogenicity of I ...... ies for a post event scenario.
@en
Safety and immunogenicity of I ...... ies for a post event scenario.
@nl
type
label
Safety and immunogenicity of I ...... ies for a post event scenario.
@en
Safety and immunogenicity of I ...... ies for a post event scenario.
@nl
prefLabel
Safety and immunogenicity of I ...... ies for a post event scenario.
@en
Safety and immunogenicity of I ...... ies for a post event scenario.
@nl
P2093
P2860
P1433
P1476
Safety and immunogenicity of I ...... ies for a post event scenario.
@en
P2093
Christine B Turley
Christine Mhorag Hay
Emmanuel B Walter
Frances K Newman
Heather R Hill
Magdalena Tary-Lehmann
Paul Chaplin
Robert A Salata
Robert B Belshe
Samer S El-Kamary
P2860
P304
P356
10.1016/J.VACCINE.2013.04.050
P407
P577
2013-05-09T00:00:00Z